Cure8 research brief
Surgeons and other clinicians managing IBD patients need to understand current biologic and immunomodulator options, their risks, and implications for surgical timing and perioperative care.
Clinicians (surgeons, gastroenterologists), patients on biologics or immunomodulators, and people facing IBD-related surgery or medication decisions.
This paper focuses on pharmacological management of IBD, covering immunomodulators and biologic agents and discussing adverse effects and contraindications relevant to perioperative care. It highlights a shift toward more personalized therapy and mentions future pharmacological developments.
The review is framed for surgeons, aiming to improve decision-making when timing surgery or managing patients on immunosuppressive drugs. It does not present new trial results but synthesizes existing literature (abstract-level content provided here).
Structured-content depth is 'abstract' from PubMed; the supplied text is an abstract-level review summary rather than a full guideline or new clinical trial. Use the full paper for detailed recommendations.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study suggests starting anti-TNF drugs early in children with Crohn's could strongly lower the chance of developing anal fistulas, a serious complication that often requires surgery. Preventing fistulas can reduce...
Patients with ulcerative colitis who cannot tolerate 5-ASA need alternative maintenance options. This study suggests azathioprine showed comparable continuation, safety, and endoscopic outcomes whether or not patients...
This paper systematically catalogs drugs that have been reported with new or worsening IBD in two large pharmacovigilance databases. Knowing which medications generate strong reporting signals can help clinicians and...
